Get a data.frame of projects, type, name and parent project
getBBDataFromProjects(projectData, qualificationProjects = NULL)A data.frame with columns `Project`, `BB-Type`, `BB-Name`, `Parent-Project`
# Get the project data from a list of paths
snapshotPaths <- list(
"Raltegravir" = file.path(
"https://raw.githubusercontent.com",
"Open-Systems-Pharmacology",
"Raltegravir-Model",
"v1.2",
"Raltegravir-Model.json"
),
"Atazanavir" = file.path(
"https://raw.githubusercontent.com",
"Open-Systems-Pharmacology",
"Atazanavir-Model",
"v1.2",
"Atazanavir-Model.json"
)
)
projectData <- getProjectsFromList(snapshotPaths)
# Get the simulations Observed Data from the projects
getBBDataFromProjects(projectData)
#> Project BB-Type
#> 1 Raltegravir Individual
#> 2 Raltegravir Compound
#> 3 Raltegravir Protocol
#> 4 Raltegravir Protocol
#> 5 Raltegravir Protocol
#> 6 Raltegravir Protocol
#> 7 Raltegravir Protocol
#> 8 Raltegravir Protocol
#> 9 Raltegravir Protocol
#> 10 Raltegravir Protocol
#> 11 Raltegravir Protocol
#> 12 Raltegravir Protocol
#> 13 Raltegravir Protocol
#> 14 Raltegravir Protocol
#> 15 Raltegravir Event
#> 16 Raltegravir Formulation
#> 17 Raltegravir Formulation
#> 18 Raltegravir Formulation
#> 19 Raltegravir Formulation
#> 20 Atazanavir Individual
#> 21 Atazanavir Individual
#> 22 Atazanavir Individual
#> 23 Atazanavir Individual
#> 24 Atazanavir Individual
#> 25 Atazanavir Individual
#> 26 Atazanavir Individual
#> 27 Atazanavir Individual
#> 28 Atazanavir Individual
#> 29 Atazanavir Compound
#> 30 Atazanavir Protocol
#> 31 Atazanavir Protocol
#> 32 Atazanavir Protocol
#> 33 Atazanavir Protocol
#> 34 Atazanavir Protocol
#> 35 Atazanavir Protocol
#> 36 Atazanavir Protocol
#> 37 Atazanavir Protocol
#> 38 Atazanavir Protocol
#> 39 Atazanavir Protocol
#> 40 Atazanavir Protocol
#> 41 Atazanavir Event
#> 42 Atazanavir Event
#> 43 Atazanavir Formulation
#> BB-Name
#> 1 Standard European Male for PEQ
#> 2 Raltegravir
#> 3 Iwamoto 2008 400mg PO (Figure 1) omeprazole study
#> 4 Iwamoto 2008 10mg PO (Figure 2) Safety-Tolerability-PK study
#> 5 Iwamoto 2008 25mg PO (Figure 2) Safety-Tolerability-PK study
#> 6 Iwamoto 2008 50mg PO (Figure 2) Safety-Tolerability-PK study
#> 7 Iwamoto 2008 100mg PO (Figure 2) Safety-Tolerability-PK study
#> 8 Iwamoto 2008 200mg PO (Figure 2) Safety-Tolerability-PK study
#> 9 Iwamoto 2008 800mg PO (Figure 2) Safety-Tolerability-PK study
#> 10 Iwamoto 2008 1200mg PO (Figure 2) Safety-Tolerability-PK study
#> 11 Iwamoto 2008 1600mg PO (Figure 2) Safety-Tolerability-PK study
#> 12 Markowitz 2006 100mg bid 10d
#> 13 Markowitz 2006 200mg bid 10d
#> 14 Markowitz 2006 400mg bid 10d
#> 15 Food
#> 16 Weibull (lactose formulation)
#> 17 chewable tablet
#> 18 filmcoated tablet (original Merck formulation)
#> 19 Weibull (granules)
#> 20 Agarwala2003
#> 21 Agarwala2005a
#> 22 Agarwala2005b
#> 23 Martin2008
#> 24 Zhu2011
#> 25 WhiteAmericanMale
#> 26 WhiteAmericanFemale
#> 27 Zhu2010
#> 28 Acosta2007
#> 29 Atazanavir
#> 30 400mg_QD_7days
#> 31 400mg_QD_6days
#> 32 400mg_QD_5days
#> 33 200mg_QD_5days
#> 34 800mg_QD_5days
#> 35 400mg_SD
#> 36 300mg_BID_7days_at120h
#> 37 300mg_BID
#> 38 200mg_QD_6days
#> 39 300mg_QD_10days
#> 40 800mg_QD_6days
#> 41 High-fat breakfast
#> 42 Light meal
#> 43 Reyataz capsule
#> Parent-Project
#> 1
#> 2
#> 3
#> 4
#> 5
#> 6
#> 7
#> 8
#> 9
#> 10
#> 11
#> 12
#> 13
#> 14
#> 15
#> 16
#> 17
#> 18
#> 19
#> 20
#> 21
#> 22
#> 23
#> 24
#> 25
#> 26
#> 27
#> 28
#> 29
#> 30
#> 31
#> 32
#> 33
#> 34
#> 35
#> 36
#> 37
#> 38
#> 39
#> 40
#> 41
#> 42
#> 43